S&P 500 Records Worst Session Since October: Investor Sentiment Dips, Fear & Greed Index In 'Neutral' Zone
GSK to buy food allergy drug maker RAPT in $2.2bn deal
This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough
GSK to buy RAPT Therapeutics for $2.2 billion